BENGALURU : Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate.AstraZeneca in June picked Emergent to help produce 300 million doses of its potential COVID-19 vaccine pledged to the United States.AstraZeneca has signed manufacturing deals globally to meet its target of making 2 billion doses of the vaccine, including with two Bill Gates-backed ventures and a $1.2 billion agreement with the U.S.
government.The company's vaccine, which has been co-developed by University of Oxford, is among the first to move into mid-stage trials.